A venture capital firm with offices in the Bay Area and Western Europe manages over $230m investing in Life Sciences companies with a stage agnostic strategy. The initial investment size ranges from $0.5 million for seed stage companies to $5 million for later stages ventures, and reserves significant capital for follow on investments. The fund invests in Europe, US and Israel.
The firm is currently looking for new investment opportunities in therapeutics, medical devices, diagnostics and digital health with a focus on cardiovascular, oncology and neurology although they are opportunistic in other areas.
The firm seeks to invest in both private and public companies based in Europe, US and Israel.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply